VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.5500
+0.0200 (3.77%)
At close: Mar 28, 2025, 4:00 PM
0.5599
+0.0099 (1.80%)
After-hours: Mar 28, 2025, 7:58 PM EST
VolitionRx Revenue
VolitionRx had revenue of $474.52K in the quarter ending September 30, 2024, with 187.22% growth. This brings the company's revenue in the last twelve months to $1.29M, up 97.50% year-over-year. In the year 2023, VolitionRx had annual revenue of $775.30K with 153.04% growth.
Revenue (ttm)
$1.29M
Revenue Growth
+97.50%
P/S Ratio
35.50
Revenue / Employee
$11,689
Employees
110
Market Cap
50.97M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
Dec 31, 2019 | 17.10K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VNRX News
- 2 days ago - Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025 - PRNewsWire
- 3 days ago - Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 - PRNewsWire
- 4 days ago - VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering - PRNewsWire
- 5 days ago - VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update - PRNewsWire
- 9 days ago - Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry - PRNewsWire
- 10 days ago - Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer - PRNewsWire
- 13 days ago - Volition Proudly Sponsors the 44th ISICEM Congress - PRNewsWire
- 17 days ago - Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems - PRNewsWire